2005-2018 年美国人类免疫缺陷病毒感染者进入护理时和开始抗逆转录病毒治疗时的 CD4 计数。

CD4 Count at Entry into Care and at Antiretroviral Therapy Prescription among Adults with Human Immunodeficiency Virus in the United States, 2005-2018.

机构信息

Department of Epidemiology, Johns Hopkins University, Baltimore, Maryland, USA.

Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

出版信息

Clin Infect Dis. 2021 Oct 5;73(7):e2334-e2337. doi: 10.1093/cid/ciaa1904.

DOI:10.1093/cid/ciaa1904

PMID:33383586

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8492212/

Abstract

From 2005 to 2018, among 32013 adults with human immunodeficiency virus entering care, median time to antiretroviral therapy (ART) prescription declined from 69 to 6 days, CD4 count at entry into care increased from 300 to 362 cells/μL, and CD4 count at ART prescription increased from 160 to 364 cells/μL.

摘要

从 2005 年到 2018 年，在进入治疗的 32013 名艾滋病毒感染者中，抗逆转录病毒治疗（ART）处方的中位时间从 69 天降至 6 天，进入治疗时的 CD4 计数从 300 个细胞/μL 增加到 362 个细胞/μL，ART 处方时的 CD4 计数从 160 个细胞/μL 增加到 364 个细胞/μL。